Exhibit 10.5


 


REGISTRATION RIGHTS AGREEMENT


 


REGISTRATION RIGHTS
AGREEMENT (this “Agreement”), dated as of March 24, 2021, by and among Cellect Biotechnology Ltd., an Israeli
company, with headquarters located at 23 Hata’as Street, Kfar Saba, Israel 44425 to be renamed “Quoin Pharmaceuticals, Ltd.”
or a similar name pursuant to the Merger Agreement (as defined below) (the “Company”), and the investors listed
on the Schedule of Buyers attached hereto (each, a “Buyer” and collectively, the “Buyers”).


 


WHEREAS:


 


A. In
connection with (i) the Securities Purchase Agreement (the “Securities Purchase Agreement”) by and among
Quoin Pharmaceuticals, Inc., a Delaware corporation (“PrivateCo”),
the Company and the Buyers of even date herewith, upon the terms and subject to the conditions of the Securities Purchase Agreement,
(x) PrivateCo has agreed to issue to each Buyer shares of common stock, par value $0.01 per share, of PrivateCo (the “PrivateCo
Common Stock”) and (y) the Company has agreed to issue Series A Warrants, Series B Warrants and Series C Warrants (each
as defined below and collectively, the “Primary Financing Warrants”) which each will be exercisable to purchase
American Depositary Shares (“ADSs”), each representing one hundred (100) of the Company’s ordinary shares,
no par value per share (the “Ordinary Shares”) (as exercised, collectively, the “Primary Financing
Warrant Shares”) in accordance with the terms of the Primary Financing Warrants and (ii) the Securities Purchase Agreement
(the “Bridge Securities Purchase Agreement”) by and among PrivateCo and the Buyers of even date herewith, PrivateCo
issued to each Buyer warrants, which are exercisable to purchase PrivateCo Common Stock,
which upon consummation of the transactions contemplated by the Merger Agreement (as defined below) will be exchanged for
identical (with references to shares of PrivateCo Common Stock appropriately adjusted to
reference ADSs and with share amounts and share prices adjusted to reflect the Exchange Ratio (as defined in the Merger Agreement))
Company warrants, which form is attached as Exhibit F to the Securities Purchase Agreement, (the “Exchange Warrants”
and together with the Primary Financing Warrants, the “Warrants”) that will be exercisable to purchase ADSs (as
exercised, collectively, the “Exchange Warrant Shares” and together with the Primary Financing Warrant Shares,
the “Warrant Shares”) in accordance with the terms of the Exchange Warrants.


 


B. In
accordance with the terms of the Securities Purchase Agreement, provided that the transactions contemplated by that certain Agreement
and Plan of Merger among the Company, CellMSC, Inc., a Delaware corporation and wholly owned subsidiary of the Company, and PrivateCo,
dated as of 24, 2021 (the “Merger Agreement”) are consummated, the Company has agreed to provide certain registration
rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute
(collectively, the “1933 Act”), and applicable state securities laws.


 






     


     


    

 


NOW, THEREFORE,
in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and each of the Buyers hereby agree as follows:




 


1. Definitions.


 


Capitalized terms used
herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement. As used
in this Agreement, the following terms shall have the following meanings:


 


(a) “Additional
Effective Date” means the date an Additional Registration Statement is declared effective by the SEC.


 


(b) “Additional
Effectiveness Deadline” means the date which is the earlier of (i) in the event that the applicable Additional Registration
Statement (x) is not subject to a full review by the SEC, the date which is thirty (30) days after the earlier of the applicable
Additional Filing Date and the Additional Filing Deadline or (y) is subject to review by the SEC, the date which is sixty (60)
days after the earlier of the applicable Additional Filing Date and the Additional Filing Deadline and (ii) the fifth (5th) Business
Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Additional Registration
Statement will not be reviewed or will not be subject to further review; provided, however, that if the Additional
Effectiveness Deadline falls on a Saturday, Sunday or other day that the SEC is closed for business, the Additional Effectiveness
Deadline shall be extended to the next Business Day on which the SEC is open for business.


 


(c) “Additional
Filing Date” means the date on which an Additional Registration Statement is filed with the SEC.


 


(d) “Additional
Filing Deadline” means if Cutback Shares are required to be included in any Additional Registration Statement, the later
of (i) the date sixty (60) days after the date substantially all of the Registrable Securities registered under the immediately
preceding Registration Statement are sold and (ii) the date six (6) months from the Demand Effective Date or the most recent Additional
Effective Date, as applicable.


 


(e) “Additional
Registrable Securities” means, (i) any Cutback Shares not previously included on a Registration Statement, and (ii) any
capital stock of the Company issued or issuable with respect to the Primary Financing Warrants, the Exchange Warrants, the Primary
Financing Warrant Shares, the Exchange Warrant Shares or the Cutback Shares, as applicable, as a result of any stock split, stock
dividend, recapitalization, exchange or similar event or otherwise, without regard to any limitations on exercise of the Warrants
and as long as the ADSs remain listed on a national recognized securities market, Ordinary Shares in the form of ADSs, and that
while any offers and sales made under a Registration Statement contemplated by this Agreement will be of ADSs, the securities to
be registered by any such Registration Statement under the 1933 Act are Ordinary Shares, and the ADSs are registered under a separate
Form F-6.


 


(f) “Additional
Registration Statement” means a registration statement or registration statements of the Company filed under the 1933
Act covering the resale of any Additional Registrable Securities.


 






    2 


     


    

 


(g) “Additional
Required Registration Amount” means any Cutback Shares not previously included on a Registration Statement, all subject
to adjustment as provided in Section 2(f), without regard to any limitations on the exercise of the Warrants.


 


(h) “Aggregate
Exercise Price” shall have the meaning set forth in the Series C Warrants.


 


(i) “Business
Day” means any day other than Saturday, Sunday or any other day on which commercial banks in the City of New York, New
York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall
not be deemed to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”,
“non-essential employee”  or any other similar orders or restrictions or the closure of any physical branch
locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers)
of commercial banks in The City of New York, New York generally are open for use by customers on such day.


 


(j) “Closing
Date” shall have the meaning set forth in the Securities Purchase Agreement.


 


(k) “Cutback
Shares” means any of the Demand Required Registration Amount and/or the Additional Required Registration Amount of Registrable
Securities not included in all Registration Statements previously declared effective hereunder as a result of a limitation on the
maximum number of ADSs permitted to be registered by the staff of the SEC pursuant to Rule 415. For the purpose of determining
the Cutback Shares, in order to determine any applicable Required Registration Amount, unless an Investor gives written notice
to the Company to the contrary with respect to the allocation of its Cutback Shares, first the Exchange Warrant Shares shall be
excluded on a pro rata basis among the Investors until all of the Exchange Warrant Shares have been excluded, second the Series
A Warrant Shares shall be excluded on a pro rata basis among the Investors until all of the Series A Warrant Shares have been excluded,
third the Series B Warrant Shares shall be excluded on a pro rata basis among the Investors until all of the Series B Warrant Shares
have been excluded and fourth the Series C Warrant Shares shall be excluded on a pro rata basis among the Investors until all of
the Series C Warrant Shares have been excluded.


 


(l) “Demand
Effective Date” means the date that a Demand Registration Statement has been declared effective by the SEC.


 


(m) “Demand
Effectiveness Deadline” means the date which is the earlier of (x) (i) in the event that the applicable Demand Registration
Statement is not subject to a full review by the SEC, sixty (60) days after the earlier of the Demand Filing Date and the Demand
Filing Deadline or (ii) in the event that the applicable Demand Registration Statement is subject to review by the SEC, one hundred
twenty (120) days after the earlier of the Demand Filing Date and the Demand Filing Deadline and (y) fifth (5th) Business
Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Demand Registration
Statement will not be reviewed or will not be subject to further review.


 






    3 


     


    

 


(n) “Demand
Filing Date” means the date on which a Demand Registration Statement is filed with the SEC.


 


(o) “Demand
Filing Deadline” means the date which is fifteen (15) Business Days after the Demand Date.


 


(p) “Demand
Registrable Securities” means (i) the Primary Financing Warrant Shares issued and issuable upon exercise of the Primary
Financing Warrants, (ii) the Exchange Warrant Shares issued and issuable upon exercise of the Exchange Warrants and (iii) any
capital stock of the Company issued and issuable with respect to the Primary Financing Warrant Shares, the Primary Financing Warrants,
the Exchange Warrant Shares or the Exchange Warrants, in each case, (x) as long as the ADSs remain listed on a national recognized
securities market, Ordinary Shares in the form of ADSs, and that while any offers and sales made under a Registration Statement
contemplated by this Agreement will be of ADSs, the securities to be registered by any such Registration Statement under the 1933
Act are Ordinary Shares, and the ADSs are registered under a separate Form F-6 and (y) as a result of any stock split, stock dividend,
recapitalization, exchange or similar event or otherwise, without regard to any limitations on the exercise of the Primary Financing
Warrants and/or the Exchange Warrants.


 


(q) “Demand
Registration Statement” means a registration statement or registration statements of the Company filed under the 1933
Act covering the resale of any Demand Registrable Securities.


 


(r) “Demand
Required Registration Amount” means the sum of (i) the maximum number of ADSs issued and issuable upon exercise of
the Series A Warrants and assuming that the Series C Warrants have been exercised in full by paying the Aggregate Exercise Price
in cash (without giving effect to any limitation on exercise set forth therein), (ii) the maximum number of ADSs issued and issuable
upon exercise of the Series B Warrants and assuming that the Series C Warrants have been exercised in full by paying the Aggregate
Exercise Price in cash (without giving effect to any limitation on exercise set forth therein), (iii) the maximum number of ADSs
issued and issuable upon exercise of the Series C Warrants, and (iv) the maximum number of ADSs issued and issuable upon exercise
of the Exchange Warrants, in each case, without giving effect to any limitation on exercise set forth in the Primary Financing
Warrants and/or the Exchange Warrants, calculated as of the Trading Day immediately preceding the applicable date of determination
and all subject to adjustment as provided in Section 2(f).


 


(s) “effective”
and “effectiveness” refer to a Registration Statement that has been declared effective by the SEC and is available
for the resale of the Registrable Securities required to be covered thereby.


 


(t) “Effective
Date” means the Demand Effective Date and/or each Additional Effective Date, as applicable.


 


(u) “Effectiveness
Deadline” means the Demand Effectiveness Deadline and/or each Additional Effectiveness Deadline, as applicable.


 






    4 


     


    

 


(v) “Eligible
Market” means the Principal Market, the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market or The New
York Stock Exchange, Inc.


 


(w) “Filing
Date” means the Demand Filing Date(s) and/or the Additional Filing Date(s), as applicable.


 


(x) “Filing
Deadline” means each Demand Filing Deadline(s) and/or each Additional Filing Deadline, as applicable.


 


(y) “Final
Reset Date” shall have the meaning ascribed to such term in the Primary Financing Warrants.


 


(z) “Investor”
means a Buyer or any transferee or assignee thereof to whom a Buyer assigns its rights under this Agreement and who agrees to become
bound by the provisions of this Agreement in accordance with Section 9 and any transferee or assignee thereof to whom a transferee
or assignee assigns its rights under this Agreement and who agrees to become bound by the provisions of this Agreement in accordance
with Section 9.


 


(aa) “Lead
Investor” means Altium Growth Fund, LP.


 


(bb) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization
and a government or any department or agency thereof.


 


(cc) “Principal
Market” means The Nasdaq Global Select Market.


 


(dd) “register,”
“registered,” and “registration” refer to a registration effected by preparing and filing one
or more Registration Statements (as defined below) in compliance with the 1933 Act and pursuant to Rule 415, and the declaration
or ordering of effectiveness of such Registration Statement(s) by the SEC.


 


(ee) “Registrable
Securities” means the Demand Registrable Securities and/or the Additional Registrable Securities, as applicable.


 


(ff) “Registration
Statement” means the Demand Registration Statement(s) and/or the Additional Registration Statement(s), as applicable.


 


(gg) “Required
Holders” means the holders of at least a majority of the Registrable Securities and shall include the Lead Investor so
long as the Lead Investor or any of its affiliates holds any Warrants or Registrable Securities.


 


(hh) “Required
Registration Amount” means either the Demand Required Registration Amount and/or the Additional Required Registration
Amount, as applicable.


 


(ii) “Rule
415” means Rule 415 promulgated under the 1933 Act or any successor rule providing for offering securities on a continuous
or delayed basis.


 






    5 


     


    

 


(jj) “SEC”
means the United States Securities and Exchange Commission.


 


(kk) “Series
A Warrants” shall have the meaning set forth in the Securities Purchase Agreement, including pursuant to Section 1(g)
thereof.


 


(ll) “Series
B Warrants” shall have the meaning set forth in the Securities Purchase Agreement, including pursuant to Section 1(g)
thereof.


 


(mm) “Series
C Warrants” shall have the meaning set forth in the Securities Purchase Agreement.


 


(nn) “Trading
Day” means any day on which the ADSs are traded on the Principal Market, or, if the Principal Market is not the principal
trading market for the ADSs on such day, then on the principal securities exchange or securities market on which the ADSs are then
traded.


 


2. Registration.


 


(a) Demand
Registrations. Upon written notice to the Company delivered by the Lead Investor at any time from and after the Closing Date
and from time to time (each such notice, a “Demand Notice” and the date(s) the Lead Investor delivers a Demand
Notice to the Company, each a “Demand Date”), the Lead Investor may require the Company to register up to the
Demand Required Registration Amount of Demand Registrable Securities not previously registered on a Demand Registration Statement
hereunder for resale pursuant to a Demand Registration Statement. The Company shall then (i) within two (2) Business Days after
the applicable Demand Date, give written notice thereof to all Investors other than the Lead Investor and (ii) prepare, and, as
soon as practicable but in no event later than the applicable Demand Filing Deadline, file with the SEC a Demand Registration Statement
on Form F-3 (or the applicable form) covering the resale of all of the Demand Registrable Securities set forth in the Demand Notice.
Upon receipt of a notice by the Company pursuant to clause (i) of the immediately preceding sentence, any Investor may notify the
Company in writing within five (5) Business Days of receipt of such notice from the Company that it wishes to have all or any portion
of its Demand Registrable Securities included in the applicable Demand Registration Statement, and the Company shall treat each
such Investor’s Demand Registrable Securities as if such Demand Registrable Securities were included in the applicable Demand Notice.
In the event that Form F-3 is unavailable for such a registration, the Company shall use such other form as is available for such
a registration on another appropriate form reasonably acceptable to the Required Holders, subject to the provisions of Section
2(e). Each Demand Registration Statement prepared pursuant hereto shall register for resale at least the number of ADSs set forth
in the applicable Demand Notice, which shall not exceed, in the aggregate, the Demand Required Registration Amount. Each Demand
Registration Statement shall contain (except if otherwise directed by the Required Holders) the “Plan of Distribution”
and “Selling Stockholders” sections in substantially the form attached hereto as Exhibit B. The Company
shall use its reasonable best efforts to have the applicable Demand Registration Statement declared effective by the SEC as soon
as practicable, but in no event later than the applicable Demand Effectiveness Deadline. By 9:30 a.m. New York time on the Business
Day following the applicable Demand Effective Date, the Company shall file with the SEC in accordance with Rule 424 under the 1933
Act the final prospectus to be used in connection with sales pursuant to such Demand Registration Statement. The Lead Investor
shall have the right to five (5) Demand Registration Statements hereunder; provided, however, the Lead Investor may
withdraw a Demand Notice and such Demand Notice shall not count as a Demand Registration Statement hereunder if the Lead Investor
bears all expenses incurred by the Company regarding such withdrawn Demand Notice; provided, further, that the Lead
Investor may withdraw a Demand Notice without bearing such expenses and without forfeiting such Demand Registration Statement if
the Lead Investor (i) has learned of a PublicCo Material Adverse Effect (as defined in the Securities Purchase Agreement) that
was not known to the Lead Investor at the time it delivered the applicable Demand Notice to the Company and (ii) has withdrawn
the applicable Demand Notice with reasonable promptness following disclosure by the Company of such PublicCo Material Adverse Effect.


 






    6 


     


    

 


(b) Additional
Mandatory Registrations. The Company shall prepare, and, as soon as practicable but in no event later than the Additional Filing
Deadline, file with the SEC an Additional Registration Statement on Form F-3 covering the resale of all of the Additional Registrable
Securities not previously registered on an Additional Registration Statement hereunder. To the extent the staff of the SEC does
not permit the Additional Required Registration Amount to be registered on an Additional Registration Statement, the Company shall
file Additional Registration Statements successively trying to register on each such Additional Registration Statement the maximum
number of remaining Additional Registrable Securities until the Additional Required Registration Amount has been registered with
the SEC. In the event that Form F-3 is unavailable for such a registration, the Company shall use such other form as is available
for such a registration on another appropriate form reasonably acceptable to the Required Holders, subject to the provisions of
Section 2(e). Each Additional Registration Statement prepared pursuant hereto shall register for resale at least that number of
ADSs equal to the Additional Required Registration Amount determined as of the date such Additional Registration Statement is initially
filed with the SEC, subject to adjustment as provided in Section 2(f). Each Additional Registration Statement shall contain (except
if otherwise directed by the Required Holders) the “Plan of Distribution” and “Selling Stockholders”
sections in substantially the form attached hereto as Exhibit B. The Company shall use its reasonable best efforts to have
each Additional Registration Statement declared effective by the SEC as soon as practicable, but in no event later than the Additional
Effectiveness Deadline. By 9:30 a.m. New York time on the Business Day following the Additional Effective Date, the Company shall
file with the SEC in accordance with Rule 424 under the 1933 Act the final prospectus to be used in connection with sales pursuant
to such Additional Registration Statement.


 


(c) Allocation
of Registrable Securities. The initial number of Registrable Securities included in any Registration Statement and any increase
or decrease in the number of Registrable Securities included therein shall be allocated pro rata among the Investors based on the
number of Registrable Securities held by each Investor at the time the Registration Statement covering such initial number of Registrable
Securities or increase or decrease thereof is declared effective by the SEC. In the event that an Investor sells or otherwise transfers
any of such Investor’s Registrable Securities, each transferee shall be allocated a pro rata portion of the then remaining number
of Registrable Securities included in such Registration Statement for such transferor. Any ADSs included in a Registration Statement
and which remain allocated to any Person which ceases to hold any Registrable Securities covered by such Registration Statement
shall be allocated to the remaining Investors, pro rata based on the number of Registrable Securities then held by such Investors
which are covered by such Registration Statement. In no event shall the Company include any securities other than Registrable Securities
on any Registration Statement without the prior written consent of the Required Holders.


 






    7 


     


    

 


(d) Legal
Counsel. Subject to Section 5 hereof, the Required Holders shall have the right to select one legal counsel to review and oversee
any registration pursuant to this Section 2 (“Legal Counsel”), which shall be Schulte Roth & Zabel LLP or
such other counsel as thereafter designated by the Required Holders. The Company and Legal Counsel shall reasonably cooperate with
each other in performing the Company’s obligations under this Agreement.


 


(e) Ineligibility
for Form F-3. In the event that Form F-3 is not available for the registration of the resale of Registrable Securities
hereunder, the Company shall (i) register the resale of the Registrable Securities on Form S-1 or another appropriate form reasonably
acceptable to the Required Holders and (ii) undertake to register the Registrable Securities on Form F-3 as soon as such
form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until
such time as a Registration Statement on Form F-3 covering the Registrable Securities has been declared effective by the
SEC.


 


(f) Sufficient
Number of Shares Registered. In the event the number of shares available under a Registration Statement filed pursuant to Section
2(a) or Section 2(b) is insufficient to cover the Required Registration Amount of Registrable Securities required to be covered
by such Registration Statement or an Investor’s allocated portion of the Registrable Securities pursuant to Section 2(c), the Company
shall amend the applicable Registration Statement, or file a new Registration Statement (on the short form available therefor,
if applicable), or both, so as to cover at least the Required Registration Amount as of the Trading Day immediately preceding the
date of the filing of such amendment or new Registration Statement, in each case, as soon as practicable, but in any event not
later than fifteen (15) days after the necessity therefor arises. The Company shall use its reasonable best efforts to cause such
amendment and/or new Registration Statement to become effective as soon as practicable following the filing thereof. For purposes
of the foregoing provision, the number of shares available under a Registration Statement shall be deemed “insufficient to
cover all of the Registrable Securities” if at any time the number of ADSs available for resale under the Registration Statement
is less than the Required Registration Amount as of such time. The calculation set forth in the foregoing sentence shall be made
without regard to any limitations on the exercise of the Warrants, such calculation shall assume that the Primary Financing Warrants
and the Exchange Warrants are then exercisable in full into a number of ADSs equal to the maximum number of ADSs as shall from
time to time be necessary to effect the exercise of all the Primary Financing Warrants and the Exchange Warrants then outstanding
without giving effect to any limitation on exercise included in the Primary Financing Warrants and/or the Exchange Warrants.


 


(g) Effect
of Failure to File and Obtain and Maintain Effectiveness of Registration Statement. If (x) a Registration Statement covering
all of the Registrable Securities required to be covered thereby and required to be filed by the Company pursuant to this Agreement
is (A) not filed with the SEC on or before the applicable Filing Deadline (a “Filing Failure”) or (B) not declared
effective by the SEC on or before the applicable Effectiveness Deadline, (an “Effectiveness Failure”) or (y) on
any day after the applicable Effective Date sales of all of the Registrable Securities required to be included on such Registration
Statement cannot be made (other than during an Allowable Grace Period (as defined in Section 3(r)) pursuant to such Registration
Statement or otherwise (including, without limitation, because of the suspension of trading or any other limitation imposed by
an Eligible Market, a failure to keep such Registration Statement effective, a failure to disclose such information as is necessary
for sales to be made pursuant to such Registration Statement, a failure to register a sufficient number of ADSs or a failure to
maintain the listing of the ADSs) (a “Maintenance Failure”), then, as partial relief for the damages to any holder
by reason of any such delay in or reduction of its ability to sell the Registrable Securities (which remedy shall not be exclusive
of any other remedies available at law or in equity, including, without limitation, specific performance or the additional obligation
of the Company to register any Cutback Shares), the Company shall pay to each holder of Registrable Securities relating to such
Registration Statement an amount in cash equal to one percent (1.0%) of the aggregate Purchase Price (as such term is defined in
the Securities Purchase Agreement) of such Investor’s Registrable Securities whether or not included in such Registration Statement
on each of the following dates: (i) the day of a Filing Failure; (ii) the day of an Effectiveness Failure; (iii) the initial day
of a Maintenance Failure; (iv) on the thirtieth day after the date of a Filing Failure and every thirtieth day thereafter (pro
rated for periods totaling less than thirty days) until such Filing Failure is cured; (v) on the thirtieth day after the date of
an Effectiveness Failure and every thirtieth day thereafter (pro rated for periods totaling less than thirty days) until such Effectiveness
Failure is cured; and (vi) on the thirtieth day after the initial date of a Maintenance Failure and every thirtieth day thereafter
(pro rated for periods totaling less than thirty days) until such Maintenance Failure is cured. No liquidated damages shall accrue
as to any Cutback Shares. The payments to which a holder shall be entitled pursuant to this Section 2(g) are referred to herein
as “Registration Delay Payments.” Registration Delay Payments shall be paid on the earlier of (I) the dates set
forth above and (II) the third Business Day after the event or failure giving rise to the Registration Delay Payments is cured.
In the event the Company fails to make Registration Delay Payments in a timely manner, such Registration Delay Payments shall bear
interest at the rate of one and one-half percent (1.5%) per month (prorated for partial months) until paid in full.


 






    8 


     


    

 


3. Related
Obligations.


 


At such time as the Company
is obligated to file a Registration Statement with the SEC pursuant to Section 2(a), 2(b), 2(e) or 2(g), the Company will use its
reasonable best efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition
thereof and, pursuant thereto, the Company shall have the following obligations:


 


(a) The
Company shall promptly prepare and file with the SEC a Registration Statement with respect to the Registrable Securities and use
its reasonable best efforts to cause such Registration Statement relating to the Registrable Securities to become effective as
soon as practicable after such filing (but in no event later than the Effectiveness Deadline). The Company shall use reasonable
best efforts to keep each Registration Statement effective pursuant to Rule 415 at all times until the earlier of (i) the date
as of which the Investors may sell all of the Registrable Securities covered by such Registration Statement without restriction
or limitation pursuant to Rule 144 and without the requirement to be in compliance with Rule 144(c)(1) (or any successor thereto)
promulgated under the 1933 Act or (ii) the date on which the Investors shall have sold all of the Registrable Securities covered
by such Registration Statement (the “Registration Period”). The Company shall ensure that each Registration Statement
(including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of
a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein (in
the case of prospectuses, in the light of the circumstances in which they were made) not misleading. The term “reasonable
best efforts” shall mean, among other things, that the Company shall submit to the SEC, within two (2) Business Days after
the later of the date that (i) the Company learns that no review of a particular Registration Statement will be made by the staff
of the SEC or that the staff has no further comments on a particular Registration Statement, as the case may be, and (ii) the approval
of Legal Counsel pursuant to Section 3(c) (which approval is immediately sought), a request for acceleration of effectiveness of
such Registration Statement to a time and date not later than two (2) Business Days after the submission of such request. The Company
shall respond in writing to comments made by the SEC in respect of a Registration Statement as soon as practicable, but in no event
later than fifteen (15) days after the receipt of comments by or notice from the SEC that an amendment is required in order for
a Registration Statement to be declared effective.


 


(b) The
Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration
Statement and the prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to Rule
424 promulgated under the 1933 Act, as may be necessary to keep such Registration Statement effective at all times during the Registration
Period, and, during such period, comply with the provisions of the 1933 Act with respect to the disposition of all Registrable
Securities of the Company covered by such Registration Statement until such time as all of such Registrable Securities shall have
been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration
Statement. In the case of amendments and supplements to a Registration Statement which are required to be filed pursuant to this
Agreement (including pursuant to this Section 3(b)) by reason of the Company filing a report on Form 10-K, Form 10-Q or Form 8-K
or any analogous report under the Securities Exchange Act of 1934, as amended (the “1934 Act”), the Company shall
have incorporated such report by reference into such Registration Statement, if applicable, or shall file such amendments or supplements
with the SEC within one (1) Trading Day of the day on which the 1934 Act report is filed which created the requirement for the
Company to amend or supplement such Registration Statement.


 


(c) The
Company shall (A) permit Legal Counsel to review and comment upon (i) a Registration Statement at least four (4) Business Days
prior to its filing with the SEC and (ii) all amendments and supplements to all Registration Statements (except for Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any similar or successor reports) within a reasonable
number of days prior to their filing with the SEC, and (B) not file any Registration Statement or amendment or supplement thereto
in a form to which Legal Counsel reasonably objects. The Company shall not submit a request for acceleration of the effectiveness
of a Registration Statement or any amendment or supplement thereto without the prior approval of Legal Counsel, which consent shall
not be unreasonably withheld. The Company shall furnish to Legal Counsel, without charge, (i) copies of any correspondence from
the SEC or the staff of the SEC to the Company or its representatives relating to any Registration Statement, (ii) unless the following
are filed with the SEC through EDGAR and are available to the public through the EDGAR system, promptly after the same is prepared
and filed with the SEC, one copy of any Registration Statement and any amendment(s) thereto, including financial statements and
schedules, all documents incorporated therein by reference, if requested by an Investor, and all exhibits and (iii) unless the
following are filed with the SEC through EDGAR and are available to the public through the EDGAR system, upon the effectiveness
of any Registration Statement, one copy of the prospectus included in such Registration Statement and all amendments and supplements
thereto. The Company shall reasonably cooperate with Legal Counsel in performing the Company’s obligations pursuant to this Section
3.


 






    9 


     


    

 


(d) The
Company shall furnish to each Investor whose Registrable Securities are included in any Registration Statement, without charge,
upon request, (i) promptly after the same is prepared and filed with the SEC, at least one copy of such Registration Statement
and any amendment(s) thereto, including financial statements and schedules, all documents incorporated therein by reference, if
requested by an Investor, all exhibits and each preliminary prospectus, (ii) upon the effectiveness of any Registration Statement,
ten (10) copies of the prospectus included in such Registration Statement and all amendments and supplements thereto (or such other
number of copies as such Investor may reasonably request) and (iii) such other documents, including copies of any preliminary or
final prospectus, as such Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable
Securities owned by such Investor.


 


(e) The
Company shall use its reasonable efforts to (i) register and qualify, unless an exemption from registration and qualification applies,
the resale by Investors of the Registrable Securities covered by a Registration Statement under such other securities or “blue
sky” laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions such amendments
(including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain
the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably necessary to maintain
such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably
necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, that the Company
shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where
it would not otherwise be required to qualify but for this Section 3(e), (y) subject itself to general taxation in any such jurisdiction,
or (z) file a general consent to service of process in any such jurisdiction. The Company shall promptly notify Legal Counsel and
each Investor who holds Registrable Securities of the receipt by the Company of any notification with respect to the suspension
of the registration or qualification of any of the Registrable Securities for sale under the securities or “blue sky”
laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threatening of any proceeding
for such purpose.


 


(f) The
Company shall notify Legal Counsel and each Investor in writing of the happening of any event, as promptly as practicable after
becoming aware of such event but in any event within one Trading Day as such event, as a result of which the prospectus included
in a Registration Statement, as then in effect, includes an untrue statement of a material fact or omission to state a material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading (provided that in no event shall such notice contain any material, nonpublic information), and, subject
to Section 3(r), promptly prepare a supplement or amendment to such Registration Statement to correct such untrue statement or
omission, and, if requested by an Investor, unless filed with the SEC through EDGAR and available to the public through the EDGAR
system, deliver one copy of such supplement or amendment to Legal Counsel and each Investor (or such other number of copies as
Legal Counsel or such Investor may reasonably request). The Company shall also promptly notify Legal Counsel and each Investor
in writing (i) when a prospectus or any prospectus supplement or post-effective amendment has been filed, and when a Registration
Statement or any post-effective amendment has become effective (notification of such effectiveness shall be delivered to Legal
Counsel and each Investor by facsimile or email on the same day of such effectiveness and by overnight mail), (ii) of any request
by the SEC for amendments or supplements to a Registration Statement or related prospectus or related information and (iii) of
the Company’s reasonable determination that a post-effective amendment to a Registration Statement would be appropriate. By 9:30
a.m. New York City time on the second Trading Day following the date any post-effective amendment has become effective, the Company
shall file with the SEC in accordance with Rule 424 under the 1933 Act the final prospectus to be used in connection with sales
pursuant to such Registration Statement.


 






    10 


     


    

 


(g) The
Company shall use its reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness of a Registration
Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction and, if such
an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment and to notify
Legal Counsel and each Investor who holds Registrable Securities being sold of the issuance of such order and the resolution thereof
or its receipt of actual notice of the initiation or threat of any proceeding for such purpose.


 


(h) If
any Investor is required under applicable securities laws to be described in the Registration Statement as an underwriter or an
Investor believes that it could reasonably be deemed to be an underwriter of Registrable Securities, at the reasonable request
of such Investor, the Company shall furnish to such Investor, on the date of the effectiveness of the Registration Statement and
thereafter from time to time on such dates as an Investor may reasonably request (i) a letter, dated such date, from the Company’s
independent certified public accountants in form and substance as is customarily given by independent certified public accountants
to underwriters in an underwritten public offering, addressed to the Investors, and (ii) an opinion, dated as of such date, of
counsel representing the Company for purposes of such Registration Statement, in form, scope and substance as is customarily given
in an underwritten public offering, addressed to the Investors.


 


(i) If
any Investor is required under applicable securities laws to be described in the Registration Statement as an underwriter or an
Investor believes that it could reasonably be deemed to be an underwriter of Registrable Securities, the Company shall make available
for inspection by (i) such Investor, (ii) Legal Counsel and (iii) one firm of accountants or other agents retained by the Investors
(collectively, the “Inspectors”), all pertinent financial and other records, and pertinent corporate documents
and properties of the Company (collectively, the “Records”), as shall be reasonably deemed necessary by each Inspector,
and cause the Company’s officers, directors and employees to supply all information which any Inspector may reasonably request;
provided, however, that each Inspector shall agree to hold in strict confidence and shall not make any disclosure (except to an
Investor) or use of any Record or other information which the Company determines in good faith to be confidential, and of which
determination the Inspectors are so notified, unless (a) the disclosure of such Records is necessary to avoid or correct a misstatement
or omission in any Registration Statement or is otherwise required under the 1933 Act, (b) the release of such Records is ordered
pursuant to a final, non-appealable subpoena or order from a court or government body of competent jurisdiction, or (c) the information
in such Records has been made generally available to the public other than by disclosure in violation of this Agreement. Each Investor
agrees that it shall, upon learning that disclosure of such Records is sought in or by a court or governmental body of competent
jurisdiction or through other means, give prompt notice to the Company and allow the Company, at its expense, to undertake appropriate
action to prevent disclosure of, or to obtain a protective order for, the Records deemed confidential. Nothing herein (or in any
other confidentiality agreement between the Company and any Investor) shall be deemed to limit the Investors’ ability to sell Registrable
Securities in a manner which is otherwise consistent with applicable laws and regulations.


 






    11 


     


    

 


(j) The
Company shall hold in confidence and not make any disclosure of information concerning an Investor provided to the Company unless
(i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information
is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information
is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental body of competent jurisdiction,
or (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement
or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning an Investor
is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt written notice to
such Investor and allow such Investor, at the Investor’s expense, to undertake appropriate action to prevent disclosure of, or
to obtain a protective order for, such information.


 


(k) The
Company shall use its reasonable best efforts either to (i) cause all of the Registrable Securities covered by a Registration Statement
to be listed on each securities exchange on which securities of the same class or series issued by the Company are then listed,
if any, if the listing of such Registrable Securities is then permitted under the rules of such exchange or (ii) secure the inclusion
for quotation of all of the Registrable Securities on the Principal Market or (iii) if, despite the Company’s reasonable best efforts,
the Company is unsuccessful in satisfying the preceding clauses (i) and (ii), to secure the inclusion for quotation on an Eligible
Market for such Registrable Securities and, without limiting the generality of the foregoing, to use its reasonable best efforts
to arrange for at least two market makers to register with the Financial Industry Regulatory Authority, Inc. (“FINRA”)
as such with respect to such Registrable Securities. The Company shall pay all fees and expenses in connection with satisfying
its obligation under this Section 3(k).


 


(l) The
Company shall cooperate with the Investors who hold Registrable Securities being offered and, to the extent applicable, facilitate
the timely preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities
to be offered pursuant to a Registration Statement and enable such certificates to be in such denominations or amounts, as the
case may be, as the Investors may reasonably request and registered in such names as the Investors may request.


 






    12 


     


    

 


(m) If
requested by an Investor, the Company shall as soon as practicable (i) incorporate in a prospectus supplement or post-effective
amendment such information as an Investor reasonably requests to be included therein relating to the sale and distribution of Registrable
Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold,
the purchase price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering;
(ii) make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to
be incorporated in such prospectus supplement or post-effective amendment; and (iii) supplement or make amendments to any Registration
Statement if reasonably requested by an Investor holding any Registrable Securities.


 


(n) The
Company shall use its reasonable best efforts to cause the Registrable Securities covered by a Registration Statement to be registered
with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable
Securities.


 


(o) The
Company shall make generally available to its security holders as soon as practical, but not later than ninety (90) days after
the close of the period covered thereby, an earnings statement (in form complying with, and in the manner provided by, the provisions
of Rule 158 under the 1933 Act) covering a twelve-month period beginning not later than the first day of the Company’s fiscal quarter
next following the applicable Effective Date of a Registration Statement.


 


(p) The
Company shall otherwise use its reasonable best efforts to comply with all applicable rules and regulations of the SEC in connection
with any registration hereunder.


 


(q) Within
two (2) Business Days after a Registration Statement which covers Registrable Securities is declared effective by the SEC, the
Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities
(with copies to the Investors whose Registrable Securities are included in such Registration Statement) confirmation that such
Registration Statement has been declared effective by the SEC in the form attached hereto as Exhibit A.


 


(r) Notwithstanding
anything to the contrary herein, at any time after the Effective Date, the Company may delay the disclosure of material, non-public
information concerning the Company and, if necessary, file a post-effective amendment to such Registration Statement to comply
with the undertakings required under Item 512(a) of Regulation S-K, the disclosure of which at the time is not, in the good faith
opinion of the Board of Directors of the Company and its counsel, in the best interest of the Company, and, in the opinion of counsel
to the Company, otherwise required (a “Grace Period”); provided, that the Company shall promptly (i) notify the
Investors in writing of the existence of material, non-public information giving rise to a Grace Period (provided that in each
notice the Company will not disclose the content of such material, non-public information to the Investors) and the date on which
the Grace Period will begin, and (ii) notify the Investors in writing of the date on which the Grace Period ends; and, provided
further, that no Grace Period shall exceed five (5) consecutive Trading Days and during any three hundred sixty five (365) day
period such Grace Periods shall not exceed an aggregate of twenty (20) days and the first day of any Grace Period must be at least
five (5) Trading Days after the last day of any prior Grace Period (each, an “Allowable Grace Period”). For purposes
of determining the length of a Grace Period above, the Grace Period shall begin on and include the date the Investors receive the
notice referred to in clause (i) and shall end on and include the later of the date the Investors receive the notice referred to
in clause (ii) and the date referred to in such notice. The provisions of Section 3(g) hereof shall not be applicable during the
period of any Allowable Grace Period. Upon expiration of the Grace Period, the Company shall again be bound by the first sentence
of Section 3(f) with respect to the information giving rise thereto unless such material, non-public information is no longer applicable.
Notwithstanding anything to the contrary, the Company shall cause its transfer agent to deliver unlegended ADSs to a transferee
of an Investor in accordance with the terms of the Securities Purchase Agreement in connection with any sale of Registrable Securities
with respect to which an Investor has entered into a contract for sale, prior to the Investor’s receipt of the notice of a Grace
Period and for which the Investor has not yet settled.


 






    13 


     


    

 


(s) Neither
the Company nor any Subsidiary or affiliate thereof shall identify any Investor as an underwriter in any public disclosure or filing
with the SEC, the Principal Market or any Eligible Market and any Investor being deemed an underwriter by the SEC shall not relieve
the Company of any obligations it has under this Agreement or any other Transaction Document (as defined in the Securities Purchase
Agreement); provided, however, that the foregoing shall not prohibit the Company from including the disclosure found in the “Plan
of Distribution” section attached hereto as Exhibit B in the Registration Statement.


 


(t) Neither
the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on
or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing
the rights granted to the Buyers in this Agreement or otherwise conflicts with the provisions hereof.


 


4. Obligations
of the Investors.


 


(a) At
least five (5) Business Days prior to the first anticipated Filing Date of a Registration Statement, the Company shall notify each
Investor in writing of the information the Company requires from each such Investor if such Investor elects to have any of such
Investor’s Registrable Securities included in such Registration Statement. It shall be a condition precedent to the obligations
of the Company to complete any registration pursuant to this Agreement with respect to the Registrable Securities of a particular
Investor that such Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by
it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect and
maintain the effectiveness of the registration of such Registrable Securities and shall execute such documents in connection with
such registration as the Company may reasonably request.


 


(b) Each
Investor, by such Investor’s acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested
by the Company in connection with the preparation and filing of any Registration Statement hereunder, unless such Investor has
notified the Company in writing of such Investor’s election to exclude all of such Investor’s Registrable Securities from such
Registration Statement.


 






    14 


     


    

 


(c) Each
Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section
3(g) or the first sentence of Section 3(f), such Investor will immediately discontinue disposition of Registrable Securities pursuant
to any Registration Statement(s) covering such Registrable Securities until such Investor’s receipt of copies of the supplemented
or amended prospectus as contemplated by Section 3(g) or the first sentence of Section 3(f) or receipt of notice that no supplement
or amendment is required. Notwithstanding anything to the contrary, the Company shall cause its transfer agent to deliver unlegended
ADSs to a transferee of an Investor in accordance with the terms of the Securities Purchase Agreement in connection with any sale
of Registrable Securities with respect to which an Investor has entered into a contract for sale prior to the Investor’s receipt
of a notice from the Company of the happening of any event of the kind described in Section 3(g) or the first sentence of Section
3(f) and for which the Investor has not yet settled.


 


(d) Each
Investor covenants and agrees that it will comply with the prospectus delivery requirements of the 1933 Act as applicable to it
or an exemption therefrom in connection with sales of Registrable Securities pursuant to the Registration Statement.


 


5. Expenses
of Registration.


 


All reasonable expenses,
other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant
to Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees, printers and accounting
fees, and fees and disbursements of counsel for the Company shall be paid by the Company. The Company shall also reimburse the
Investors for the fees and disbursements of Legal Counsel in connection with the registration, filing or qualification pursuant
to Sections 2 and 3 of this Agreement in an amount of up to $15,000 per registration statement.


 


6. Indemnification.


 


In the event any Registrable
Securities are included in a Registration Statement under this Agreement:


 


(a) To
the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, the
directors, officers, partners, members, employees, agents, representatives of, and each Person, if any, who controls any Investor
within the meaning of the 1933 Act or the 1934 Act (each, an “Indemnified Person”), against any losses, claims,
damages, liabilities, judgments, fines, penalties, charges, costs, reasonable attorneys’ fees, amounts paid in settlement or expenses,
joint or several (collectively, “Claims”), incurred in investigating, preparing or defending any action, claim,
suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative
or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a
party thereto (“Indemnified Damages”), to which any of them may become subject insofar as such Claims (or actions
or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or
alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment thereto or in any filing
made in connection with the qualification of the offering under the securities or other “blue sky” laws of any jurisdiction
in which Registrable Securities are offered (“Blue Sky Filing”), or the omission or alleged omission to state
a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) any untrue statement
or alleged untrue statement of a material fact contained in any preliminary prospectus if used prior to the effective date of such
Registration Statement, or contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof
or supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the
statements made therein, in light of the circumstances under which the statements therein were made, not misleading, (iii) any
violation or alleged violation by the Company of the 1933 Act, the 1934 Act, any other law, including, without limitation, any
state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant
to a Registration Statement or (iv) any violation of this Agreement (the matters in the foregoing clauses (i) through (iv) being,
collectively, “Violations”). For the avoidance of doubt, the Violations set forth in this Section 6(a) are intended
to apply, and shall apply, to direct claims asserted by any Buyer against the Company as well as any third party claims asserted
by an Indemnified Person (other than a Buyer) against the Company. Subject to Section 6(c), the Company shall reimburse the Indemnified
Persons, promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable expenses incurred
by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein,
the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim by an Indemnified Person arising out
of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company
by such Indemnified Person for such Indemnified Person expressly for use in connection with the preparation of the Registration
Statement or any such amendment thereof or supplement thereto, if such prospectus was timely made available by the Company pursuant
to Section 3(d); and (ii) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the
prior written consent of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain
in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer
of the Registrable Securities by the Investors pursuant to Section 9.


 






    15 


     


    

 


(b) In
connection with any Registration Statement in which an Investor is participating, each such Investor agrees to severally and not
jointly indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company,
each of its directors, each of its officers who signs the Registration Statement and each Person, if any, who controls the Company
within the meaning of the 1933 Act or the 1934 Act (each, an “Indemnified Party”), against any Claim or Indemnified
Damages to which any of them may become subject, under the 1933 Act, the 1934 Act or otherwise, insofar as such Claim or Indemnified
Damages arise out of or are based upon any Violation, in each case to the extent, and only to the extent, that such Violation occurs
in reliance upon and in conformity with written information furnished to the Company by such Investor expressly for use in connection
with such Registration Statement; and, subject to Section 6(c), such Investor shall reimburse the Indemnified Party for any legal
or other expenses reasonably incurred by an Indemnified Party in connection with investigating or defending any such Claim; provided,
however, that the indemnity agreement contained in this Section 6(b) and the agreement with respect to contribution contained in
Section 7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent
of such Investor, which consent shall not be unreasonably withheld or delayed; provided, further, however, that the Investor shall
be liable under this Section 6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to
such Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement. Such indemnity shall remain
in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer
of the Registrable Securities by the Investors pursuant to Section 9.


 


(c) Promptly
after receipt by an Indemnified Person or Indemnified Party under this Section 6 of notice of the commencement of any action or
proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall,
if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party
a written notice of the commencement thereof, and, the indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense
thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the
case may be; provided, however, that an Indemnified Person or Indemnified Party shall have the right to retain its own counsel
with the fees and expenses of not more than one counsel for all such Indemnified Person or Indemnified Party to be paid by the
indemnifying party, if, in the reasonable opinion of counsel retained by the Indemnified Person or Indemnified Party, as applicable,
the representation by such counsel of the Indemnified Person or Indemnified Party, as the case may be, and the indemnifying party
would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and
any other party represented by such counsel in such proceeding. In the case of an Indemnified Person, legal counsel referred to
in the immediately preceding sentence shall be selected by the Investors holding at least a majority in interest of the Registrable
Securities included in the Registration Statement to which the Claim relates. The Indemnified Party or Indemnified Person shall
reasonably cooperate with the indemnifying party in connection with any negotiation or defense of any such action or Claim by the
indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or
Indemnified Person which relates to such action or Claim. The indemnifying party shall keep the Indemnified Party or Indemnified
Person fully apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying
party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent, provided,
however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall,
without the prior written consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into
any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff
to such Indemnified Party or Indemnified Person of a release from all liability in respect to such Claim or litigation and such
settlement shall not include any admission as to fault on the part of the Indemnified Party. Following indemnification as provided
for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect
to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver
written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such
indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section 6, except to the extent that
the indemnifying party is prejudiced in its ability to defend such action. The provisions of this Section 6(c) shall not apply
to direct claims between the Company and a Buyer.


 






    16 


     


    

 


(d) The
indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred.


 


(e) The
indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party
or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject
to pursuant to the law.


 


7. Contribution.


 


To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however,
that: (i) no Person involved in the sale of Registrable Securities which Person is guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the 1933 Act) in connection with such sale shall be entitled to contribution from any Person involved
in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller
of Registrable Securities shall be limited in amount to the amount of net proceeds received by such seller from the sale of such
Registrable Securities pursuant to such Registration Statement.


 


8. Reports
Under the 1934 Act.


 


With a view to making
available to the Investors the benefits of Rule 144 promulgated under the 1933 Act or any other similar rule or regulation of the
SEC that may at any time permit the Investors to sell securities of the Company to the public without registration (“Rule
144”), the Company agrees to, so long as an Investor owns Registrable Securities:


 


(a) make
and keep public information available, as those terms are understood and defined in Rule 144;


 


(b) file
with the SEC in a timely manner all reports and other documents required of the Company under the 1933 Act and the 1934 Act so
long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the
applicable provisions of Rule 144; and


 


(c) furnish
to each Investor so long as such Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company,
if true, that it has complied with the reporting requirements of Rule 144, the 1933 Act and the 1934 Act, (ii) a copy of the most
recent annual or quarterly report of the Company and such other reports and documents so filed by the Company (unless such report
or document is already publicly available), and (iii) such other information as may be reasonably requested to permit the Investors
to sell such securities pursuant to Rule 144 without registration.


 






    17 


     


    

 


9. Assignment
of Registration Rights.


 


The rights under this
Agreement shall be automatically assignable by the Investors to any transferee of all or any portion of such Investor’s Registrable
Securities if: (i) the Investor agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement
is furnished to the Company within a reasonable time after such assignment; (ii) the Company is, within a reasonable time after
such transfer or assignment, furnished with written notice of (a) the name and address of such transferee or assignee, and (b)
the securities with respect to which such registration rights are being transferred or assigned; (iii) immediately following such
transfer or assignment the further disposition of such securities by the transferee or assignee is restricted under the 1933 Act
or applicable state securities laws; (iv) at or before the time the Company receives the written notice contemplated by clause
(ii) of this sentence the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained
herein; and (v) such transfer shall have been made in accordance with the applicable requirements of the Securities Purchase Agreement.


 


10. Amendment
of Registration Rights.


 


Provisions of this Agreement
may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively
or prospectively), only with the written consent of the Company and the Required Holders. Any amendment or waiver effected in accordance
with this Section 10 shall be binding upon each Investor and the Company. No such amendment shall be effective to the extent that
it applies to less than all of the holders of the Registrable Securities. No consideration shall be offered or paid to any Person
to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration (other than the
reimbursement of legal fees) also is offered to all of the parties to this Agreement.


 


11. Miscellaneous.


 


(a) Notwithstanding
anything herein to the contrary, the Exchange Warrant Shares shall not be deemed “Registrable Securities” hereunder to
the extent the Exchange Warrant Shares are freely tradable by the holders thereof without any restriction or limitation (including,
for the avoidance of doubt, if the holder thereof exercises the Exchange Warrants by paying the applicable Exercise Price (as defined
in the Exchange Warrants) in cash).


 


(b) A
Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable
Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the
same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from such record
owner of such Registrable Securities.


 






    18 


     


    

 


(c) Any
notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be
in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon delivery, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party), (iii) upon delivery, when sent by electronic mail (provided that the sending party does not receive an automated rejection
notice); or (iv) one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly
addressed to the party to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications shall
be:


 


If to the Company:


 


Cellect Biotechnology Ltd.


23 Hata’as Street


Kfar Saba, Israel 44425


Attention: Shai Yarkoni, CEO


Email: shai@cellect.co


 


With a copy (for informational
purposes only) to:


 


Horn &
Co. - Law Offices


Amot Investment
Tower, 24 Floor


2 Weizmann
Street,


Tel Aviv,
Israel


Attention:
Yuva Horn, Adv.


Email: yhorn@hornlaw.co.il


 


and:


 


Royer Cooper
Cohen Braunfeld LLC


101 West
Elm Street, Suite 400


Conshohocken,
PA 19428


Attention:
David Gitlin, Esq.


Email: DGitlin@rccblaw.com


 


If to the Transfer Agent:


 


	 	Computershare	 
	 	480 Washington Blvd., Jersey City, NJ 07310 USA 	 
	 	Telephone:	201 680 2388	 
	 	Facsimile:	201 680 4606	 
	 	Attention:	Mr. Brian Cossin, Relationship Management	 
	 	E-mail:	brian.cossin@computershare.com	 



 


If to Legal Counsel:


 


	 	Schulte Roth & Zabel LLP	 
	 	919 Third Avenue	 
	 	New York, New York  10022	 
	 

         
	Telephone:	(212) 756-2000	 
	 	Facsimile:	(212) 593-5955	 
	 	Attention:	Eleazer Klein, Esq.	 
	 	Email:	eleazer.klein@srz.com	 



 


If to a Buyer, to its address, facsimile
number or email address set forth on the Schedule of Buyers attached hereto, with copies to such Buyer’s representatives as set
forth on the Schedule of Buyers, or to such other address, facsimile number and/or email address to the attention of such other
Person as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness
of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication,
(B) mechanically or electronically generated by the sender’s facsimile machine or e-mail transmission containing the time, date,
recipient facsimile number or e-mail address and an image of the first page of such transmission or (C) provided by a courier or
overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized
overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.


 






    19 


     


    

 


(d) Failure
of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or
remedy, shall not operate as a waiver thereof.


 


(e) All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal
laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the
State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the
State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy
thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT
TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT
OR ANY TRANSACTION CONTEMPLATED HEREBY.


 


(f) If
any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or
unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s),
the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).


 






    20 


     


    

 


(g) This
Agreement, the other Transaction Documents (as defined in the Securities Purchase Agreement) and the instruments referenced herein
and therein constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. There
are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein. This Agreement,
the other Transaction Documents and the instruments referenced herein and therein supersede all prior agreements and understandings
among the parties hereto with respect to the subject matter hereof and thereof.


 


(h) Subject
to the requirements of Section 9, this Agreement shall inure to the benefit of and be binding upon the permitted successors and
assigns of each of the parties hereto.


 


(i) The
headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.


 


(j) This
Agreement may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute
one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission
or electronic mail of a copy of this Agreement bearing the signature of the party so delivering this Agreement.


 


(k) Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.


 


(l) All
consents and other determinations required to be made by the Investors pursuant to this Agreement shall be made, unless otherwise
specified in this Agreement, by the Required Holders, determined as if all of the Warrants held by Investors then outstanding have
been exercised for Registrable Securities without regard to any limitations on exercise of the Warrants.


 


(m) The
language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules
of strict construction will be applied against any party.


 


(n) This
Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person.


 


(o) The
obligations of each Investor hereunder are several and not joint with the obligations of any other Investor, and no provision of
this Agreement is intended to confer any obligations on any Investor vis-à-vis any other Investor. Nothing contained herein,
and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as
a group with respect to such obligations or the transactions contemplated herein.


 


* * * * * *


[Signature Page Follows]


 




    21


     


    

 


IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed
as of the date first written above.


 


	 	COMPANY:
	 	 
	 	Cellect Biotechnology Ltd.
	 	 	 
	 	By:	        
	 	 	Name:
	 	 	Title:   


 


[Signature Page to Registration Rights Agreement]


 



     


     


    

 


IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed
as of the date first written above.


 





	 	BUYERS:
	 	 
	 	Altium Growth Fund, LP
	 	 	 
	 	By:	 
	 	 	 
	 	By:	
	 	 	Name:
	 	 	Title:   


 


[Signature Page to Registration Rights Agreement]


 




     


     


    

 


SCHEDULE OF BUYERS


 


	 

        Buyer

        
	 	Buyer
    Address, Facsimile 

    Number and E-mail	 	Buyer’s
    Representative’s Address, Facsimile Number and E-Mail
	Altium Growth Fund, LP	 	
        c/o Altium Capital Management,
LP

        152 West 57th Street, 20th Floor

        New York, NY 10019

        Attention: Joshua Thomas

        Telephone: 212-259-8404

        E-mail: jthomas@altiumcap.com
	 	
        Schulte Roth & Zabel
LLP

        919 Third Avenue

        New York, NY 10022

        Attn: Eleazer Klein, Esq.

        Facsimile: (212) 593-5955

        Telephone: (212) 756-2000

        Email: eleazer.klein@srz.com



 


 




     


     


    

 


EXHIBIT A


 


FORM OF NOTICE OF EFFECTIVENESS

OF REGISTRATION STATEMENT


 


[●]


[●]


[●]





	Telephone:	[●] 	 
	Facsimile:	[●] 	 
	Attention:	[●] 	 
	E-mail:	[●] 	 



 


Re:      [Quoin
Pharmaceuticals, Ltd.]


 


Ladies and Gentlemen:


 


[We are][I am] counsel
to [Quoin Pharmaceuticals, Ltd.], an Israeli company (formerly known as Cellect Biotechnology Ltd.) (the “Company”)
pursuant to that certain Agreement and Plan of Merger among the Company, CellMSC, Inc., a Delaware corporation and wholly owned
subsidiary of the Company, and Quoin Pharmaceuticals, Inc., a Delaware corporation (“PrivateCo”), dated as of
March 24, 2021 (the “Merger Agreement”), and have represented PrivateCo, and from and after the completion of
the transactions contemplated by the Merger Agreement, the Company, in connection with (i) that certain Securities Purchase Agreement,
dated as of March 24, 2021, entered into by and among PrivateCo, and the buyers named therein (collectively, the “Holders”)
pursuant to which PrivateCo issued to the Holders warrants exercisable for shares of PrivateCo’s common stock, par value $0.01
per share, which were exchanged for identical PublicCo warrants to purchase ADSs (as defined below) (the “Exchange Warrants”)
and (ii) that certain Securities Purchase Agreement, dated as of March 24, 2021, entered into by and among the Company, PrivateCo,
and the Holders pursuant to which PrivateCo issued to the Holders shares of common stock, par value $0.01 per share, of PrivateCo,
and the Company issued to the Holders three series of warrants (together with the Exchange Warrants, the “Warrants”)
exercisable for the Company’s American Depositary Shares (“ADSs”), each representing one hundred (100) of the
Company’s ordinary shares, no par value per share (the “Ordinary Shares”).
The Company also has entered into a Registration Rights Agreement with the Holders (the “Registration Rights Agreement”)
pursuant to which the Company agreed, among other things, to register the resale of the Registrable Securities (as defined in the
Registration Rights Agreement), including the ADSs issued and issuable upon exercise of the Warrants under the Securities Act of
1933, as amended (the “1933 Act”). In connection with the Company’s obligations under the Registration Rights
Agreement, on ____________ ___, 20__, the Company filed a Registration Statement on Form F-3 (File No. 333-_____________) (the
“Registration Statement”) with the Securities and Exchange Commission (the “SEC”) relating to
the Registrable Securities which names each of the Holders as a selling stockholder thereunder.


 


In connection with the
foregoing, [we][I] advise you that a member of the SEC’s staff has advised [us][me] by telephone that the SEC has entered an order
declaring the Registration Statement effective under the 1933 Act at [ENTER TIME OF EFFECTIVENESS] on [ENTER
DATE OF EFFECTIVENESS] and [we][I] have no knowledge, after telephonic inquiry of a member of the SEC’s staff, that any
stop order suspending its effectiveness has been issued or that any proceedings for that purpose are pending before, or threatened
by, the SEC and the Registrable Securities are available for resale under the 1933 Act pursuant to the Registration Statement.


 


This letter shall serve
as our standing instruction to you that the ADSs are freely transferable by the Holders pursuant to the Registration Statement.
You need not require further letters from us to effect any future legend-free issuance or reissuance of ADSs to the Holders as
contemplated by the Company’s Irrevocable Transfer Agent Instructions dated [●].


 





	 	Very truly yours,
	 	 
	 	[ISSUER’S COUNSEL]
	 	 	 
		By:	         
	CC:[LIST NAMES OF HOLDERS]	 	 



 




    A-1 


     


    

 


EXHIBIT B


SELLING STOCKHOLDERS


 


The ADSs being offered
by the selling stockholders are those issued and issuable to the selling stockholders, upon exercise of the warrants. For additional
information regarding the issuances of those ADSs and the warrants, see “Private Placement of Purchased Shares and Warrants”
above. We are registering the ADSs in order to permit the selling stockholders to offer the shares for resale from time to time.
Except for the ownership of the ADSs and the warrants, the selling stockholders have not had any material relationship with us
within the past three years.


 


The table below lists
the selling stockholders and other information regarding the beneficial ownership of the ADSs by each of the selling stockholders.
The second column lists the number of ADSs beneficially owned by each selling stockholder, based on its ownership of the ADSs and
the warrants, as of ________, 20__, assuming exercise of the warrants held by the selling stockholders on that date, without regard
to any limitations on exercises.


 


The third column lists
the ADSs being offered by this prospectus by the selling stockholders.


 


In accordance with
the terms of a registration rights agreement with the selling stockholders, this prospectus generally covers the resale of sum
of the (i) maximum number of ADSs issued and issuable upon exercise of the Series A Warrants and assuming that the Series C Warrants
have been exercised in full by paying the Aggregate Exercise Price (as defined in the Series C Warrants) in cash (without giving
effect to any limitation on exercise set forth therein), (ii) maximum number of ADSs issued and issuable upon exercise of the Series
B Warrants and assuming that the Series C Warrants have been exercised in full by paying the Aggregate Exercise Price in cash (without
giving effect to any limitation on exercise set forth therein), (iii) maximum number of ADSs issued and issuable upon exercise
of the Series C Warrants, and (iv) maximum number of ADSs issued and issuable upon exercise of the Exchange Warrants, in each case,
determined as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date this registration
statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination
and all subject to adjustment as provided in the registration right agreement, without regard to any limitations on the exercise
of the warrants, and this registration statement registers the maximum number of ADSs as shall from time to time be necessary to
effect the exercise of all the Primary Financing Warrants (assuming that the Series C Warrants have been exercised in full by paying
the Aggregate Exercise Price in cash (without giving effect to any limitation on exercise set forth therein)) and the Exchange
Warrants, then outstanding without giving effect to any limitation on exercise included in the Primary Financing Warrants and/or
the Exchange Warrants. The fourth column assumes the sale of all of the shares offered by the selling stockholders pursuant to
this prospectus.


 


Under the terms of
the warrants, a selling stockholder may not exercise the warrants to the extent such exercise would cause such selling stockholder,
together with its affiliates, to beneficially own a number of Ordinary Shares (including, for the avoidance of doubt, any Ordinary
Shares underlying the ADSs) which would exceed 4.99% or 9.99%, as applicable, of our then outstanding Ordinary Shares following
such exercise, excluding for purposes of such determination ADSs issuable upon exercise of the warrants which have not been exercised.
The number of shares in the second column does not reflect this limitation. The selling stockholders may sell all, some or none
of their shares in this offering. See “Plan of Distribution.”


 




    B-1 


     


    

 


	





Name of Selling Stockholder	 	Number of ADSs 

Owned Prior to Offering	 	Maximum Number of ADSs to be Sold Pursuant to this Prospectus	 	Number of ADSs 

Owned After

 Offering	 	Percentage of ADSs Owned After Offering if Greater than 1%
	
         Altium Growth Fund, LP
(1)

        
	 	 	 	 	 	0	 	 
	[Other Buyers] (2)	 	 	 	 	 	 	 	 


 


* Denotes less than
1%.


 


(1) Altium Capital
Management, LP, the investment manager of Altium Growth Fund, LP, has voting and investment power over these securities. Jacob
Gottlieb is the managing member of Altium Capital Growth GP, LLC, which is the general partner of Altium Growth Fund, LP. Each
of Altium Growth Fund, LP and Jacob Gottlieb disclaims beneficial ownership over these shares.


 


(2)


 




    B-2 


     


    

 


PLAN OF DISTRIBUTION


 


We are registering
the ADSs issued and issuable upon exercise of the warrants to permit the resale of these ADSs by the holders of the ADSs warrants
from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders
of the ADSs. We will bear all fees and expenses incident to our obligation to register the ADSs.


 


The selling stockholders
may sell all or a portion of the ADSs beneficially owned by them and offered hereby from time to time directly or through one or
more underwriters, broker-dealers or agents. If the ADSs are sold through underwriters or broker-dealers, the selling stockholders
will be responsible for underwriting discounts or commissions or agent’s commissions. The ADSs may be sold in one or more transactions
at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated
prices. These sales may be effected in transactions, which may involve crosses or block transactions,


 


		●	on any national securities exchange or quotation service on which the securities may be listed
or quoted at the time of sale;



 


		●	in the over-the-counter market;



 


		●	in transactions otherwise than on these exchanges or systems or in the over-the-counter market;



 


		●	through the writing of options, whether such options are listed on an options exchange or otherwise;



 


		●	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;



 


		●	block trades in which the broker-dealer will attempt to sell the shares as agent but may position
and resell a portion of the block as principal to facilitate the transaction;



 


		●	purchases by a broker-dealer as principal and resale by the broker-dealer for its account;



 


		●	an exchange distribution in accordance with the rules of the applicable exchange;



 


		●	privately negotiated transactions;



 


		●	short sales;



 


		●	sales pursuant to Rule 144;



 


		●	broker-dealers may agree with the selling securityholders to sell a specified number of such shares
at a stipulated price per share;



 


		●	a combination of any such methods of sale; and



 


		●	any other method permitted pursuant to applicable law.



 


If the selling stockholders
effect such transactions by selling ADSs to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers
or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions
from purchasers of the ADSs for whom they may act as agent or to whom they may sell as principal (which discounts, concessions
or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions
involved). In connection with sales of the ADSs or otherwise, the selling stockholders may enter into hedging transactions with
broker-dealers, which may in turn engage in short sales of the ADSs in the course of hedging in positions they assume. The selling
stockholders may also sell ADSs short and deliver ADSs covered by this prospectus to close out short positions and to return borrowed
shares in connection with such short sales. The selling stockholders may also loan or pledge ADSs to broker-dealers that in turn
may sell such shares.


 


The selling stockholders
may pledge or grant a security interest in some or all of the warrants or ADSs owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell the ADSs from time to time pursuant to this prospectus
or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933, as amended,
amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as
selling stockholders under this prospectus. The selling stockholders also may transfer and donate the ADSs in other circumstances
in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes
of this prospectus.


 






    B-3 


     


    

 


The selling stockholders
and any broker-dealer participating in the distribution of the ADSs may be deemed to be “underwriters” within the meaning
of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed
to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the ADSs is made, a
prospectus supplement, if required, will be distributed which will set forth the aggregate amount of ADSs being offered and the
terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms
constituting compensation from the selling stockholders and any discounts, commissions or concessions allowed or reallowed or paid
to broker-dealers.


 


Under the securities
laws of some states, the ADSs may be sold in such states only through registered or licensed brokers or dealers. In addition, in
some states the ADSs may not be sold unless such shares have been registered or qualified for sale in such state or an exemption
from registration or qualification is available and is complied with.


 


There can be no assurance
that any selling stockholder will sell any or all of the ADSs registered pursuant to the registration statement, of which this
prospectus forms a part.


 


The selling stockholders
and any other person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act
of 1934, as amended, and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange Act,
which may limit the timing of purchases and sales of any of the ADSs by the selling stockholders and any other participating person.
Regulation M may also restrict the ability of any person engaged in the distribution of the ADSs to engage in market-making activities
with respect to the ADSs. All of the foregoing may affect the marketability of the ADSs and the ability of any person or entity
to engage in market-making activities with respect to the ADSs.


 


We will pay all expenses
of the registration of the ADSs pursuant to the registration rights agreement, estimated to be $[     ]
in total, including, without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities
or “blue sky” laws; provided, however, that a selling stockholder will pay all underwriting discounts and selling commissions,
if any. We will indemnify the selling stockholders against liabilities, including some liabilities under the Securities Act, in
accordance with the registration rights agreements, or the selling stockholders will be entitled to contribution. We may be indemnified
by the selling stockholders against civil liabilities, including liabilities under the Securities Act, that may arise from any
written information furnished to us by the selling stockholder specifically for use in this prospectus, in accordance with the
related registration rights agreement, or we may be entitled to contribution.


 


Once sold under the
registration statement, of which this prospectus forms a part, the ADSs will be freely tradable in the hands of persons other than
our affiliates.


 


 


B-4